Glancy Prongay Wolke & Rotter LLP reminds Phreesia Inc. shareholders of a July 13, 2026 deadline to move for lead plaintiff in a class action over alleged securities fraud. The suit covers investors who bought Phreesia common stock between May 8, 2025 and March 30, 2026. On March 30, 2026, after the market closed, Phreesia sharply lowered its fiscal 2027 revenue growth projections, citing worsening visibility and weaker pharmaceutical marketing commitments in its Network Solutions segment. The next day, the stock fell $3.03, or 26.6%, to close at $8.38 per share. The complaint alleges that during the class period, defendants misled investors about the reliability of the company’s long-term growth outlook and the durability of its pharmaceutical marketing revenue, while downplaying risks to the 2027 revenue target.
Phreesia IncCompany lowered fiscal 2027 revenue guidance, triggering a 26.6% stock drop and a securities fraud lawsuit.